Search Results - "HOLBRECHTS, S"

Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial by Demols, A., Borbath, I., Van den Eynde, M., Houbiers, G., Peeters, M., Marechal, R., Delaunoit, T., Goemine, J.-C., Laurent, S., Holbrechts, S., Paesmans, M., Van Laethem, J.-L.

“…There is a high unmet clinical need for treatments of advanced/metastatic biliary tract cancers after progression on first-line chemotherapy. Regorafenib has…”
Get full text

Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice by Bregni, G., Akin Telli, T., Camera, S., Deleporte, A., Moretti, L., Bali, A.M., Liberale, G., Holbrechts, S., Hendlisz, A., Sclafani, F.

“…•The mainstay of treatment for locally advanced rectal cancer is (chemo) radiotherapy and surgery.•Trials have not given clear indications on the added value…”
Get full text

Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors by Demols, A., Borbath, I., Van den Eynde, M., Houbiers, G., Peeters, M., Marechal, R., Delaunoit, T., Goeminne, J., Laurent, S., Holbrechts, S., Paesmans, M., Van Laethem, J.

Get full text

Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations by BERGHMANS, T, PASLEAU, F, LECOMTE, J, LOUVIAUX, I, MARKIEWICZ, E, MEERT, A. P, RICHEZ, M, ROELANDTS, M, SCHERPEREEL, A, TULIPPE, Ch, VAN HOUTTE, P, VAN SCHIL, P, PAESMANS, M, WACHTERS, C, WESTEEL, V, SCULIER, J. P, BONDUELLE, Y, CADRANEL, J, TOTH, I. Cs, GARCIA, C, GINER, V, HOLBRECHTS, S, LAFITTE, J. J

“…The present systematic review was performed under the auspices of the European Lung Cancer Working Party (ELCWP) in order to determine the role of early…”
Get full text

Primitive pulmonary "malignant epithelioid hemangioendothelioma" versus epithelioid angiosarcoma. A case report and review of the literature by Donfut, A L, Lemaitre, J, Van de Walle, H, Holbrechts, S, Carlier, P, Winant, C, Lebrun, E

“…We describe the case of a 56-year-old man presenting a primary pulmonary epithelioid angiosarcoma versus malignant epithelioid hemangioendothelioma still…”
Get full text

A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer by Berghmans, T, Van Houtte, P, Paesmans, M, Giner, V, Lecomte, J, Koumakis, G, Richez, M, Holbrechts, S, Roelandts, M, Meert, A.P, Alard, S, Leclercq, N, Sculier, J.P

“…Abstract As concomitant chemoradiotherapy for stage III NSCLC is associated with survival advantage in comparison to a sequential approach, we conducted a…”
Get full text

406 Phase 2 study of XL184 in a cohort of patients (pts) with castration resistant prostate cancer (CRPC) and measurable soft tissue disease by Smith, D.C, Spira, A, Grève, J. De, Hart, L, Holbrechts, S, Lin, C.C, Hussain, M, Herrick, S, Houggy, K, Vogelzang, N

Get full text

107TiP Dry powder inhaled cisplatin in stage IV NSCLC: The phase I/IIa CIS-DPI-01 study by Brandão, M., Holbrechts, S., Sonnet, W., Fung, S., Rosière, R., De Coninck, F., Berghmans, T.

Get full text

P-276 Sex and regorafenib toxicity in refractory colorectal cancer: A safety analysis of the RegARd-C trial by Vandeputte, C., Bregni, G., Paraskevas, G., Guiot, T., Kehagias, P., Deleporte, A., Geboes, K., Delaunoit, T., Demolin, G., Peeters, M., D'Hondt, L., Janssens, J., Carrasco, J., Holbrechts, S., Goeminne, J., Vergauwe, P., Van Laethem, J., Flamen, P., Hendlisz, A., Sclafani, F.

Get full text

O-003Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors by Demols, A, Borbath, I, den Eynde, M Van, Houbiers, G, Peeters, M, Marechal, R, Delaunoit, T, Goeminne, J, Laurent, S, Holbrechts, S, Paesmans, M, Laethem, J Van

Get full text

Treatment of small cell lung cancer: limited disease. Guidelines of clinical practice made by the European Lung Cancer Working Party by Holbrechts, S, Roelandts, M

“…These updated clinical practice guidelines on the treatment of small cell lung cancer (SCLC) limited disease formulated by the ELCWP aim to answer the…”
Get full text

115P BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study by Martins-Branco, D., Franzoi, M.A., Nader-Marta, G., Gombos, A., Vanhaudenarde, V., De Maio D'Esposito, E., Goncalves, A., Clatot, F., Holbrechts, S., Cheymol, C., Borcoman, E., Denys, H., Gligorov, J., Kindt, N., Abu-Serieh, B., Paesmans, M., Awada, A.H., Kotecki, N.

Get full text

569P - Somore Trial: Combining Sorafenib (SOR) with Capecitabine (CAP) Yields Highly Encouraging Survival Results and Elevated Metabolic Response Rate in Chemorefractory Metastatic Colorectal Cancer (MCRC) by Deleporte, A., Hendlisz, A., Delaunoit, T., Marechal, R., Peeters, M., Holbrechts, S., van den Eynde, M., Houbiers, G., Moreau, M., Flamen, P.

“…Several phases I and II trials including mCRC and metastatic breast cancer patients have suggested an interesting clinical activity in solid tumors with a…”
Get full text

Somore Trial: Combining Sorafenib (SOR) with Capecitabine (CAP) Yields Highly Encouraging Survival Results and Elevated Metabolic Response Rate in Chemorefractory Metastatic Colorectal Cancer (MCRC) by Deleporte, A., Hendlisz, A., Delaunoit, T., Marechal, R., Peeters, M., Holbrechts, S., van den Eynde, M., Houbiers, G., Moreau, M., Flamen, P.

Get full text

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer by Berghmans, Thierry, Scherpereel, Arnaud, Meert, Anne-Pascale, Giner, Vicente, Lecomte, Jacques, Lafitte, Jean-Jacques, Leclercq, Nathalie, Paesmans, Marianne, Sculier, Jean-Paul

“…In a literature meta-analysis, we showed survival benefits for regimens including cisplatin [hazard ratio (HR) 0.61; 95% confidence interval (CI), 0.57-0.66]…”
Get full text

Weekly Versus Biweekly Combination of Docetaxel (D)-Cisplatin (C)-5Fu (F) in Advanced Gastric Cancer and Esogastric Junction Adenocarcinoma (Agc): Doge Study by Deleporte, A., Eynde, M. van den, Forget, F., Holbrechts, S., Delaunoit, T., Houbiers, G., Kalantari, H. Rezaei, Laurent, S., Vanderstraeten, E., De Man, M., Vergauwe, P., Clausse, M., Vanderauwera, J., Pierre, P., D'Hondt, L., Ghillemijn, B., Covas, A., Paesmans, M., Ameye, L., Hendlisz, A.

Get full text

624PWEEKLY VERSUS BIWEEKLY COMBINATION OF DOCETAXEL (D)-CISPLATIN (C)-5FU (F) IN ADVANCED GASTRIC CANCER AND ESOGASTRIC JUNCTION ADENOCARCINOMA (AGC): DOGE STUDY by Deleporte, A., Eynde, M. van den, Forget, F., Holbrechts, S., Delaunoit, T., Houbiers, G., Kalantari, H. Rezaei, Laurent, S., Vanderstraeten, E., Man, M. De, Vergauwe, P., Clausse, M., Vanderauwera, J., Pierre, P., D'Hondt, L., Ghillemijn, B., Covas, A., Paesmans, M., Ameye, L., Hendlisz, A.

“…Abstract Aim: Triweekly DCF is a standard treatment in aGC, but is, however, associated with a bleak 30% febrile neutropenia (FN) incidence requiring…”
Get full text

P-194 A feasibility study preparing to a phase III randomised trialcomparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. A trial conducted by the European Lung Cancer Working Party (ELCWP) by Berghmans, T., Sculier, J., Recloux, P., Van Cutsem, O., Efremidis, A., Holbrechts, S., Roelandts, M., Fraikin, J., Ninane, V., Van Houtte, P.

Get full text

Primitive Pulmonary "Malignant Epithelioid Hemangioendothelioma" versus Epithelioid Angiosarcoma A Case Report and Review of the Literature by Donfut, A.-L., Lemaitre, J., Walle, H. Van de, Holbrechts, S., Carlier, P., Winanf, C., Lebrun1, E.

“…We describe the case of a 56-year-old man presenting a primary pulmonary epithelioid angiosarcoma versus malignant epithelioid hemangioendothelioma still…”
Get full text